• AstraZeneca announced in August that it had reached agreements in principle on monetary terms with attorneys representing approximately 17,500 Seroquel product-liability claimants in the United States for approximately $198 million. The agreements in principle are subject to agreement on nonmonetary terms. The settlement stems from claims that the company marketed Seroquel, which is approved for treatment of psychosis, for off-label indications.